KTR rolls out projects worth Rs.800 cr in Genome Valley

Telangana Minister of Industries KT Rama Rao has unveiled several new projects in Genome Valley to the tune of Rs 800 crores on Thursday. The projects represent biosimilars manufacturing, advanced pharma and biotech R&D, formulation manufacturing and integrated turnkey lab spaces for high-tech research, signifying the large breadth of capabilities present in Genome Valley, which has emerged as Asia’s largest high innovation and life sciences cluster.

Hyderabad-based GeneSys Biologics, a specialty biotech company, inaugurated its biotechnology manufacturing facility. The company plans to deploy around Rs 350-400 crores overall in their facility.

The minister congratulated the entire GeneSys team on their achievement and quoted “Biosimilars are expected to be the next big growth segment within the biopharma industry due to their enhanced capabilities in healthcare and patient safety. Given the extraordinary strengths of Telangana in vaccines and pharmaceuticals, we have taken various initiatives focused on accelerating biologics and biosimilars development as part of the Genome Valley 2.0 Vision. I am thrilled to see companies like Genesys Biologics pursuing this opportunity aggressively.”

Dr Pankaj Bhai Patel, chairman of Cadila Healthcare, who graced the occasion, said, “Representing the scientific community, I am delighted to see a high-tech cluster such as Genome Valley. Genesys shows a lot of promise and potential and they are at the right place to grow their operations.”

In another major boost to the Genome Valley cluster, the fastest growing Canadian generic drug manufacturer (40 per



cent annual growth) JAMP Pharma will be setting up its biggest centre of excellence for R&D and manufacturing of export quality drug formulations and will invest around Rs 250 crores with generation of 2,000 direct jobs over the next 24 months.

Gracing the occasion of the company’s ground breaking ceremony, Monsieur Louis Pilon, Global President and CEO of Jamp Pharma Corporation met the Minister.

KTR assured him of complete support of the State authorities and requested Monsieur Pilon to consider scaling up Jamp Pharma’s operations in Hyderabad gradually, introducing a larger product share of the company’s portfolio including cutting-edge R&D activities.

Dr Dutta, chief scientific officer of Jamp Pharma said, “The decision to set up a state-of-the-art R&D and manufacturing facility of Jamp Pharma Corporation was taken on November 2017 and after a global hunt for a suitable place for setting up of the facility, Hyderabad was selected, being the capital of Pharmaceutical industry and discussions were initiated with the Life Science Team of the Govt of Telangana. I am happy to inform you that within three months’ time the entire process has been completed seamlessly and in a hassle free manner, as we are accustomed to do in US or Canada”.

Global President and CEO Louis Pilon said, “Availability of talent and world-class infrastructure supported by Government’s commitment in the sector were the key reasons of choosing Hyderabad. We are committed to build a world-class facility generating new jobs and usher development.”